Notably, no patients have experienced side effects greater than Grade III classification, suggesting that this therapy has an acceptable safety profile.71 A clinical trial testing the efficacy of B7-H3 CAR T-cell locoregional therapy in treating DIPG/DMG and recurrent and refractory CNS tumors is also currently underway [NCT04185038].72 Preliminary data on two treated patients have revealed detectable B7-H3 CAR T cells in their cerebrospinal fluid. This evidence concerns the gene CD276 and diffuse intrinsic pontine glioma.